Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer
Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer
复制标题
细胞因子诱导杀伤细胞免疫治疗联合一线化疗治疗转移性结直肠癌的疗效回顾性分析
DOI：
10.1002/cti2.1113
复制
发表时间：
2020-01-01
影响因子：
5.8
通讯作者：
Xia, Jian-Chuan
中科院分区：
文献类型：
--
作者：
Pan, Qiu-Zhong;Gu, Jia-Mei;Xia, Jian-Chuan
目的以氟嘧啶为基础的化疗方案是目前转移性结直肠癌的一线治疗方案，但疗效往往不理想。本研究旨在探讨细胞因子诱导杀伤细胞(CIK)细胞免疫治疗与一线化疗联合治疗mCRC的疗效。其中，126例患者仅接受一线化疗(对照组)，另126例患者在人口学和临床特征相似的情况下，接受CIK细胞免疫治疗联合一线化疗(CIK组)。结果CIK组中位生存时间为54.7个月，对照组为24.1个月；中位无进展生存时间为14.6个月，中位生存时间为25.7个月。单因素和多因素分析表明，CIK细胞治疗是影响患者OS和PFS的独立预后因素。亚组分析显示，CIK细胞治疗显著改善了转移性结肠癌患者的OS和PFS，但对转移性直肠癌患者没有影响。此外，CD3(+)CD56(+)亚群的变化可能是CIK细胞治疗成功的一个指标：CD3(+)CD56(+)亚群增加的患者比CD3(+)CD56(+)亚群减少的患者生存更好。结论细胞因子诱导的杀伤细胞免疫治疗联合一线化疗可显著改善mCRC患者的OS和PFS，尤其是对转移性结肠癌患者。
Objectives Fluoropyrimidine-based chemotherapy regimens are the current first-line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory. The present study aimed to determine the effect of combined cytokine-induced killer (CIK) cell immunotherapy and first-line chemotherapy in patients with mCRC.Methods This retrospective study included 252 patients with mCRC treated with first-line chemotherapy. Among them, 126 patients received first-line chemotherapy only (control group), while the other 126 patients, with similar demographic and clinical characteristics, received CIK cell immunotherapy combined with first-line chemotherapy (CIK group). Overall survival (OS) and progression-free survival (PFS) were compared between the two groups using the Kaplan-Meier method.Results The median OS for the CIK group was 54.7 versus 24.1 months for the controls, and the median PFS for the CIK group was 25.7 versus 14.6 months for the controls. Univariate and multivariate analyses indicated that CIK cell treatment was an independent prognostic factor for patients' OS and PFS. Subgroup analyses showed that CIK cell treatment significantly improved the OS and PFS of patients with metastatic colon cancer, but not those with metastatic rectal cancer. Additionally, the change in CD3(+)CD56(+) subsets after the fourth treatment cycle might be an indicator of successful CIK cell treatment: Patients with increased CD3(+)CD56(+) subsets had better survival than those with decreased CD3(+)CD56(+) subsets.Conclusion Cytokine-induced killer cell immunotherapy combined with first-line chemotherapy could significantly improve the OS and PFS of patients with mCRC, particularly for patients with metastatic colon cancer.